SUBSCRIBE
SUBSCRIBE

Phase I

Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
AstraZeneca PLC’s Immunotherapy Lung Cancer Combo Treatment Sees Breakthrough in Early Stage Trial
February 8, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Lab Criticized as ‘Slow to React’ in Bial’s Fatal Drug Trial
February 5, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
With Almost $200 Million in the Bank, WAVE Life Sciences Plans Six Clinical Programs in Three Years
January 29, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Akashi Halts DMD Clinical Trial, Third Company to Recently Have Problems With DMD Drug Trials
January 26, 2016
 · 
3 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Questions Remain as to What Caused the Bial Trial Tragedy in France
January 19, 2016
 · 
2 min read
Pfizer and Allergan Execs Emphasize Joint Company’s Pipeline, Hint Job Cuts Will Be Minimal
Drug Development
Biogen’s Promising Pipeline Underscores CEO’s High-Risk Strategy
January 18, 2016
 · 
4 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Drugmaker Unnamed as Botched Trial in France Leaves One Patient Brain Dead and Five Hospitalized
January 15, 2016
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Business
Booming Moderna Eyes Six Human Trials in 2016, Inks Deals with AstraZeneca PLC, Merck & Co. and Signed Huge Lease in Cambridge for R&D Growth
January 12, 2016
 · 
3 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Drug Development
RestorGenex and Diffusion Pharma Merge to Form Wholly-Owned Oncology Subsidiary
December 28, 2015
 · 
2 min read
Drug Development
KaloBios Fires Martin Shkreli, UC Davis Suspends Leukemia Trial Due to Shkreli
December 21, 2015
 · 
3 min read
Load More
PRESS RELEASES
Drug Development
4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023
April 27, 2023
 · 
11 min read
Drug Development
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris
April 26, 2023
 · 
11 min read
Drug Development
Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting
April 26, 2023
 · 
4 min read
Drug Development
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
 · 
19 min read
Drug Development
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
April 26, 2023
 · 
19 min read
Drug Development
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
April 26, 2023
 · 
2 min read
Drug Development
eFFECTOR to Present Updated Clinical Data from Phase 2 Expansion Cohorts for Zotatifin in Patients with ER+ Metastatic Breast Cancer at ASCO 2023 Annual MeetingeFFECTOR to host conference call following ASCO presentation
April 26, 2023
 · 
2 min read
Drug Development
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023
April 26, 2023
 · 
6 min read
Drug Development
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
 · 
5 min read
Drug Development
Biofrontera Inc. Announces Last Patient Out in Phase I Study to Evaluate Safety and Tolerability in Treating Actinic Keratosis Using 3 Tubes of Ameluz(R)
April 26, 2023
 · 
4 min read
Drug Development
Bicara Therapeutics Announces Oral Presentation of Head and Neck Cancer Dose Expansion Data from Phase 1/1b Study of BCA101 at Upcoming 2023 ASCO Annual Meeting
April 26, 2023
 · 
2 min read
Drug Development
Theseus Pharmaceuticals Initial Dose Escalation Results from Ongoing Phase 1/2 Trial of THE-630 Accepted for Online Publication at 2023 ASCO Annual Meeting
April 26, 2023
 · 
5 min read
Drug Development
Bolt Biotherapeutics to Present Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Tumors at 2023 ASCO Annual Meeting
April 26, 2023
 · 
7 min read
Drug Development
Artiva Biotherapeutics Announces Presentation of Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
April 26, 2023
 · 
3 min read
Drug Development
ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the Knee
April 26, 2023
 · 
6 min read
Drug Development
Direct Biologics Receives FDA Clearance to Initiate Phase 1b/2a Clinical Trial of ExoFlo™ in Patients with Medically Refractory Perianal Fistulizing Crohn’s Disease
April 26, 2023
 · 
4 min read
Drug Development
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration - April 26, 2023
April 26, 2023
 · 
11 min read
Drug Development
Calico Life Sciences Announces First Participant Dosed in Phase 1b Clinical Study Evaluating ABBV-CLS-7262 for the Treatment of Vanishing White Matter Disease
April 26, 2023
 · 
4 min read
Drug Development
Avenge Bio Announces Successful Completion of First Dose Level Cohort in Phase 1/2 Clinical Trial of AVB-001 for the Treatment of Ovarian Cancer
April 26, 2023
 · 
3 min read
Drug Development
Alentis Therapeutics Reports Positive Topline Results From Phase 1 Multiple-ascending Dose Cohorts Study
April 26, 2023
 · 
2 min read
Load More